Estrogen receptor beta repurposes EZH2 to suppress oncogenic NFκB/p65 signaling in triple negative breast cancer.
NPJ Breast Cancer
; 8(1): 20, 2022 Feb 17.
Article
in En
| MEDLINE
| ID: mdl-35177654
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Prognostic_studies
Language:
En
Journal:
NPJ Breast Cancer
Year:
2022
Document type:
Article
Affiliation country:
Estados Unidos
Country of publication:
Estados Unidos